BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/21/2025 9:40:07 AM | Browse: 55 | Download: 105
 |
Received |
|
2024-09-25 15:02 |
 |
Peer-Review Started |
|
2024-09-25 15:02 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2024-10-24 02:21 |
 |
Revised |
|
2024-11-06 03:25 |
 |
Second Decision |
|
2024-12-09 02:40 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2024-12-09 09:00 |
 |
Articles in Press |
|
2024-12-09 09:00 |
 |
Publication Fee Transferred |
|
2024-11-07 14:50 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2025-01-13 01:44 |
 |
Publish the Manuscript Online |
|
2025-01-21 09:22 |
ISSN |
2218-4333 (online) |
Open Access |
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Case Report |
Article Title |
Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Fei-Fei Wei, Jing Zhang, Zhe Jia, Zhi-Chao Yao and Chun-Qiao Chen |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Guangxi Guilin Science and Technology Fund |
20190218-7-6 |
|
Corresponding Author |
Chun-Qiao Chen, MD, Department of Oncology, People’s Hospital of Guilin, No. 12 Wenming Road, Guilin 541002, Guangxi Zhuang Autonomous Region, China. chencq8302@163.com |
Key Words |
Furmonertinib; Osimertinib; Lung adenocarcinoma; Interstitial lung disease; Case report |
Core Tip |
We report a case of a 56-year-old woman who was diagnosed with lung adenocarcinoma with lung hilum, mediastinal lymph nodes and brain metastases (T4N3M1c stage IVB). The patient received targeted treatment with osimertinib after radiotherapy and chemotherapy, but she developed interstitial lung disease following osimertinib treatment. After active treatment, her lung injury improved. The patient was retreated with furmonertinib combined with prednisone and did not experience interstitial lung disease again. So far, she has survived for 14 months without disease progression. This study suggests that retreatment with furmonertinib under steroid coverage could be considered as an effective therapeutic option after careful risk-benefit assessment for patients with epidermal growth factor receptor-mutant lung adenocarcinoma. |
Publish Date |
2025-01-21 09:22 |
Citation |
<p>Wei FF, Zhang J, Jia Z, Yao ZC, Chen CQ. Furmonertinib re-challenge for epidermal growth factor receptor-mutant lung adenocarcinoma after osimertinib-induced interstitial lung disease: A case report. <i>World J Clin Oncol</i> 2025; 16(3): 101766</p> |
URL |
https://www.wjgnet.com/2218-4333/full/v16/i3/101766.htm |
DOI |
https://dx.doi.org/10.5306/wjco.v16.i3.101766 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345